Fusion protein of SARS-CoV-2, and vaccine composition of fusion protein
The invention belongs to the technical field of biology, and particularly relates to a fusion protein of SARS-CoV-2, and a vaccine composition of the fusion protein. The fusion protein and the prepared vaccine composition containing the fusion protein overcome the defects of poor immunogenicity and the like of subunit vaccines, can induce the specific immune response aiming at SARS-CoV-2, and achieve the purposes of inhibiting the replication of SARS-CoV-2, inhibiting the spread of SARS-CoV-2 or preventing the settlement of SARS-CoV-2 common strains and variant strains in SARS-CoV-2 host bodies. The fusion protein and the vaccine composition containing the fusion protein can effectively prevent and/or treat novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19). The fusion protein can be recombined and expressed in large quantities by the aid of the genetic engineering technology, the consumed time is short, and the large-scale production can be facilitated..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 15. Sept. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU ZHONGQIU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-09-15, Last update posted on www.tib.eu: 2022-07-11, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111662389 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA00656139X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA00656139X | ||
| 003 | DE-627 | ||
| 005 | 20230504115732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA00656139X | ||
| 035 | |a (EPA)CN111662389 | ||
| 035 | |a (EPA)72386943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU ZHONGQIU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fusion protein of SARS-CoV-2, and vaccine composition of fusion protein |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-09-15, Last update posted on www.tib.eu: 2022-07-11, Last updated: 2023-02-09 | ||
| 520 | |a The invention belongs to the technical field of biology, and particularly relates to a fusion protein of SARS-CoV-2, and a vaccine composition of the fusion protein. The fusion protein and the prepared vaccine composition containing the fusion protein overcome the defects of poor immunogenicity and the like of subunit vaccines, can induce the specific immune response aiming at SARS-CoV-2, and achieve the purposes of inhibiting the replication of SARS-CoV-2, inhibiting the spread of SARS-CoV-2 or preventing the settlement of SARS-CoV-2 common strains and variant strains in SARS-CoV-2 host bodies. The fusion protein and the vaccine composition containing the fusion protein can effectively prevent and/or treat novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19). The fusion protein can be recombined and expressed in large quantities by the aid of the genetic engineering technology, the consumed time is short, and the large-scale production can be facilitated. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LIAO GUOCHAO |4 aut | |
| 700 | 0 | |a KE CHANGWEN |4 aut | |
| 700 | 0 | |a QI XIAOXIAO |4 aut | |
| 700 | 0 | |a KE BIXIA |4 aut | |
| 700 | 0 | |a YANG DEYING |4 aut | |
| 700 | 0 | |a WU PENG |4 aut | |
| 700 | 0 | |a LU LINLIN |4 aut | |
| 700 | 0 | |a FENG QIAN |4 aut | |
| 700 | 0 | |a WANG CAIYAN |4 aut | |
| 700 | 0 | |a LI ZIBO |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 15. Sept. |
| 773 | 1 | 8 | |g year:2020 |g day:15 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/72386943/publication/CN111662389A1?q=CN111662389 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 15 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 15 |c 09 | ||